Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial-Reference-Cited by-同舟云学术

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

Published:2020 Issue:6 Volume:5 Page:e001079
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Albiges Laurence^ORCID,Tannir Nizar M.,Burotto Mauricio,McDermott David,Plimack Elizabeth R.,Barthélémy Philippe,Porta Camillo^ORCID,Powles Thomas,Donskov Frede,George Saby,Kollmannsberger Christian K.,Gurney Howard,Grimm Marc-Oliver,Tomita Yoshihiko,Castellano Daniel,Rini Brian I.,Choueiri Toni K.,Saggi Shruti Shally,McHenry M. Brent,Motzer Robert J.

Funder

Memorial Sloan-Kettering Cancer Center

Bristol Myers Squibb

National Institutes of Health

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference15 articles.

Cited by 395 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Organ-Specific Tumor Response to Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study;Clinical Genitourinary Cancer;2024-10

2. Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de‐differentiation (ARON‐1 study);International Journal of Cancer;2024-09-07

3. Can Cytoreductive Nephrectomy Improve Outcomes of Nivolumab Treatment in Patients with Metastatic Clear-Cell Renal Carcinoma?;Current Oncology;2024-09-04

4. Identification of RNMT as an immunotherapeutic and prognostic biomarker: From pan-cancer analysis to lung squamous cell carcinoma validation;Immunobiology;2024-09

5. Randomized phase 2 dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma;Annals of Oncology;2024-09